Evidence map›Paper›PMID 42012169›Full record

ArticleJournal of Parkinson's disease2026

Rethinking our strategies to develop disease-modifying therapies for Parkinson's: Time for combination therapies?

Paloma Fernandez, Rachel M Hughes, Helen Matthews, Joy Duffen, Radi Haloub, Anthony H Schapira, Simon Rw Stott

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Paloma FernandezCure Parkinson's, London, UK.ORCID 0009-0001-5087-8116
Rachel M HughesCure Parkinson's, London, UK.ORCID 0009-0004-8473-5297
Helen MatthewsCure Parkinson's, London, UK.
Joy DuffenCure Parkinson's, London, UK.
Radi HaloubUniversity College London, London, UK.ORCID 0000-0002-7645-3677
Anthony H SchapiraUniversity College London, London, UK.ORCID 0000-0002-3018-3966
Simon Rw StottCure Parkinson's, London, UK.ORCID 0000-0002-5741-4664

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant advances in our understanding of Parkinson's disease (PD) over the last three decades, no disease-modifying therapies (DMTs) have been identified. There is considerable effort focused on this goal, but the challenges in achieving it are illustrated by the limited number of DMTs advancing to late-stage Phase 3 clinical testing (see annual

Indexed as

Antiparkinson AgentsParkinson DiseaseDrug Therapy, CombinationHumansAntiparkinson Agentsclinical trialscombination therapiesdisease-modifying therapiesParkinson's disease

Identifiers

PMID42012169
PMCPMC13435205

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.